乙型肝炎病毒包膜蛋白嵌合抗原受体抑制乙型肝炎表面抗原分泌
本研究基于靶向HBV大包膜蛋白和小包膜蛋白的单链可变片段(MA18/7-scFv和G12-scFv)构建多种嵌合抗原受体(CAR),在细胞模型和HBV小鼠模型中研究其对HBsAg分泌和HBV感染的影响及机制。结果显示G12-scFv-Fc和G12-CAR-Fc在HBV小鼠模型中使血清HBsAg最高抑制达130倍,腺相关病毒载体递送时抑制效果持续至少8周;结论认为CAR除用于T细胞治疗外还具有直接抗病毒活性,Fc连接的G12-scFv和G12-CARs可能为降低循环HBsAg提供新方法。
要点
- MA18/7-scFv和CARs可阻断HBV感染和病毒颗粒分泌。
- G12-scFv优先抑制病毒颗粒分泌,其CAR格式和Fc连接版本均阻断HBsAg分泌。
- G12-scFv-Fc和G12-CAR-Fc在HBV小鼠模型中使血清HBsAg最高抑制达130倍。
核心结论
- CARs除众所周知的T细胞治疗应用外,还具有直接抗病毒活性。
- Fc连接的G12-scFv和G12-CARs可能为降低循环HBsAg提供新方法。
研究设计与样本
- 基于靶向HBV大包膜蛋白和小包膜蛋白的单链可变片段MA18/7-scFv和G12-scFv分别构建多种嵌合抗原受体(CARs)。
- 使用多种细胞培养模型和HBV小鼠模型广泛研究其对HBsAg分泌和HBV感染的影响及潜在机制。
主要发现
- 经分泌信号肽介导转位至内质网和分泌途径后,MA18/7-scFv和CARs阻断HBV感染和病毒颗粒分泌。
- G12-scFv优先抑制病毒颗粒分泌,而其CAR格式和可结晶片段(Fc)连接版本均阻断HBsAg分泌。
- G12-scFv和G12-CAR主要将HBV包膜蛋白阻滞在内质网,并强效抑制HBV出芽。
- G12-scFv-Fc和G12-CAR-Fc在HBV小鼠模型中使血清HBsAg最高抑制达130倍。
- 通过腺相关病毒载体递送时,抑制效果持续至少8周。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Chronic hepatitis B (CHB) caused by HBV infection greatly increases the risk of liver cirrhosis and hepatocellular carcinoma. Hepatitis B surface antigen (HBsAg) plays critical roles in the pathogenesis of CHB. HBsAg loss is the key indicator for cure of CHB, but is rarely achieved by current approved anti-HBV drugs. Therefore, novel anti-HBV strategies are urgently needed to achieve sustained HBsAg loss. DESIGN: We developed multiple chimeric antigen receptors (CARs) based on single-chain variable fragments (scFvs, namely MA18/7-scFv and G12-scFv), respectively, targeting HBV large and small envelope proteins. Their impacts on HBsAg secretion and HBV infection, and the underlying mechanisms, were extensively investigated using various cell culture models and HBV mouse models. RESULTS: After secretory signal peptide mediated translocation into endoplasmic reticulum (ER) and secretory pathway, MA18/7-scFv and CARs blocked HBV infection and virion secretion. G12-scFv preferentially inhibited virion secretion, while both its CAR formats and crystallisable fragment (Fc)-attached versions blocked HBsAg secretion. G12-scFv and G12-CAR arrested HBV envelope proteins mainly in ER and potently inhibited HBV budding. Furthermore, G12-scFv-Fc and G12-CAR-Fc strongly suppressed serum HBsAg up to 130-fold in HBV mouse models. The inhibitory effect lasted for at least 8 weeks when delivered by an adeno-associated virus vector. CONCLUSION: CARs possess direct antiviral activity, besides the well-known application in T-cell therapy. Fc attached G12-scFv and G12-CARs could provide a novel approach for reducing circulating HBsAg.
引用
- Wang Y, Li Q, Li C, et al. Chimeric antigen receptors of HBV envelope proteins inhibit hepatitis B surface antigen secretion. Gut. 2024. PMID: 37973365. doi:10.1136/gutjnl-2023-330537
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。